A Potent MAPK13-14 Inhibitor Prevents Airway Inflammation and Mucus Production
Overview
Molecular Biology
Physiology
Pulmonary Medicine
Authors
Affiliations
Common respiratory diseases continue to represent a major public health problem, and much of the morbidity and mortality is due to airway inflammation and mucus production. Previous studies indicated a role for mitogen-activated protein kinase 14 (MAPK14) in this type of disease, but clinical trials are unsuccessful to date. Our previous work identified a related but distinct kinase known as MAPK13 that is activated in respiratory airway diseases and is required for mucus production in human cell-culture models. Support for MAPK13 function in these models came from effectiveness of versus gene-knockdown and from first-generation MAPK13-14 inhibitors. However, these first-generation inhibitors were incompletely optimized for blocking activity and were untested in vivo. Here we report the next generation and selection of a potent MAPK13-14 inhibitor (designated NuP-3) that more effectively downregulates type-2 cytokine-stimulated mucus production in air-liquid interface and organoid cultures of human airway epithelial cells. We also show that NuP-3 treatment prevents respiratory airway inflammation and mucus production in new minipig models of airway disease triggered by type-2 cytokine challenge or respiratory viral infection. The results thereby provide the next advance in developing a small-molecule kinase inhibitor to address key features of respiratory disease. This study describes the discovery of a potent mitogen-activated protein kinase 13-14 (MAPK13-14) inhibitor and its effectiveness in models of respiratory airway disease. The findings thereby provide a scheme for pathogenesis and therapy of lung diseases [e.g., asthma, chronic obstructive pulmonary disease (COPD), Covid-19, postviral, and allergic respiratory disease] and related conditions that implicate MAPK13-14 function. The findings also refine a hypothesis for epithelial and immune cell functions in respiratory disease that features MAPK13 as a possible component of this disease process.
A first-in-kind MAPK13 inhibitor that can correct stem cell reprogramming and post-injury disease.
Zhang Y, Wu K, Mao D, Iberg C, Yin-DeClue H, Sun K bioRxiv. 2024; .
PMID: 39229202 PMC: 11370402. DOI: 10.1101/2024.08.21.608990.
A correctable immune niche for epithelial stem cell reprogramming and post-viral lung diseases.
Wu K, Zhang Y, Yin-DeClue H, Sun K, Mao D, Yang K J Clin Invest. 2024; 134(18).
PMID: 39052353 PMC: 11405052. DOI: 10.1172/JCI183092.
MAPK13 controls structural remodeling and disease after epithelial injury.
Wu K, Zhang Y, Mao D, Iberg C, Yin-DeClue H, Sun K bioRxiv. 2024; .
PMID: 38895360 PMC: 11185504. DOI: 10.1101/2024.05.31.596863.
Rehman T, Pezzulo A, Thurman A, Zemans R, Welsh M JCI Insight. 2024; 9(14.
PMID: 38888974 PMC: 11383177. DOI: 10.1172/jci.insight.181836.
Durstenfeld M, Weiman S, Holtzman M, Blish C, Pretorius R, Deeks S Ann N Y Acad Sci. 2024; 1535(1):31-41.
PMID: 38593220 PMC: 11500513. DOI: 10.1111/nyas.15132.